(This is the third blank-check company, or SPAC, sponsored by an affiliate of Eli Casdin, founder and chief investment officer of Casdin Capital, and Keith Meister, founder and chief investment officer of Corvex Management, two leading investment firms. Mr. Casdin is the CEO of CM Life Sciences III, Inc., and Mr. Meister is the chairman.) We […]

(Note: This is a blank-check company or SPAC offering of Class A ordinary shares. This is NOT a unit offering (stock and warrants) that is typical of SPAC IPOs.) We intend to capitalize on our management team’s background and experience to identify innovative companies in the biotechnology sector that are domiciled in North America or […]

The company intends to focus on operating businesses in the gaming and e-commerce sectors in the Greater China, Japan and Southeast Asia regions. (This is a newly organized blank-check company or SPAC incorporated in the British Virgin Islands.)

We are committed to providing cost-effective mobile devices to consumers globally and to helping low-income individuals from established markets, including the United States, and emerging markets, including India and countries in South Asia and Africa, have better access to updated mobile technology. (Incorporated in the Cayman Islands) We are mainly engaged in the design, development, production, sales […]

The UFC (the Ultimate Fighting Championship – mixed martial arts), IMG (sports, events, media and New York Fashion Week) and  WME (William Morris Endeavor, the entertainment and sports talent agency) have one thing in common: All are owned by Endeavor Group Holdings, the sports and entertainment company that grew out of Beverly Hills talent agency […]

We are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. Our company was founded on the premise that the upper nasal cavity can be […]

We are a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile […]

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our product pipeline is focused on rare gastrointestinal, or GI, disorders. Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like […]

  Our mission is to empower financial institutions to grow confidently, adapt quickly and build thriving digital communities. Alkami is a cloud-based digital banking platform. We inspire and empower community, regional and super-regional financial institutions (“FIs”) to compete with large, technologically advanced and well-resourced banks in the United States. Our solution, the Alkami Platform, allows […]

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). We are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy […]